Median TechnologiesEURONEXT: ALMDT

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30, 2026

· Issued by Median Technologies via Business Wire

Summary by 6ix AI

Median Technologies, a French company offering AI-based medical imaging software and services for cancer diagnosis and oncology trials, reported a total of 49,071,263 shares in its capital as of September 30, 2026.

Key details

  • Real voting rights totalled 48,998,813, which excludes treasury shares (shares the company holds in itself). Theoretical voting rights, which include treasury shares, totalled 49,048,063.
  • The company's Class E preference shares carry no voting rights.
  • Of the 14,424,541 warrants (BSA, rights to subscribe for shares) issued in connection with the 2025 capital increase, 12,261,125 remained outstanding and exercisable as of September 30, 2026.
  • The figures are disclosed under article L-223-8 II of the French Commercial Code and article 223-16 of the General Regulations of the AMF, France's financial markets regulator.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/median-technologies-disclosure-of-total-number-of-voting-rights-and-number-of-shares-in-the-capital-as-of-september-30-2026

MEDIAN TECHNOLOGIES

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

49,071,263

Number of real voting rights* (excluding treasury shares**)

48,998,813

Theoretical number of voting rights* (including treasury shares**)

49,048,063

(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations

Furthermore, as of September 30, 2026, out of the 14,424,541 warrants (BSA) issued in connection with the 2025 capital increase, 12,261,125 remained outstanding and exercisable.

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261012676084/en/

Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Investors – SEITOSEI ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com

Press – MAARC
Bruno Arabian
+33 6 87 88 47 26
bruno.arabian@maarc.fr

View original source (Business Wire)Median Technologies on 6ix

Story so far

Earlier from Median Technologies

Later from Median Technologies

All Median Technologies news releases